LYEL Stock Analysis: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$17.31
-0.61 (-3.40%)
▼
5d:
-9.84%
30d:
-27.91%
90d:
-31.8%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
LYEL is down 7.2% this week, but smart money is accumulating calls. Top strike: $27 2026-06-18 with 1 OI. Call ratio: 100% View Scanner →
Strength: 8.6/10
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: LYEL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: LYEL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $17.31, which is considered oversold relative to its 30-day fair value range of $19.37 to $23.79.
Technical Outlook: Technically, LYEL is in a downtrend. The price is currently testing key support at $17.43. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: LYEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (74th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $37.17 (+107.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LYEL is in a downtrend. The price is currently testing key support at $17.43. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: LYEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (74th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $37.17 (+107.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$19.37 -
$23.79
Company Quality Score
44/100
(HOLD)
Options IV Signal
74th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
41.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 74th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 107.4% below Wall St target ($37.17)
Trading Range Analysis
30-Day Trading Range
$19.37 -
$23.79
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.81
(22.0%)
Support & Resistance Levels
Support Level
$17.43
Resistance Level
$21.48
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.12
Wall Street Target
$37.17
(+107.4%)
Revenue Growth (YoY)
-71.4%
Share & Embed Analysis
Last updated: May 18, 2026 10:44 AM ET
Data refreshes hourly during market hours. Next update: 11:44 AM
Data refreshes hourly during market hours. Next update: 11:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Lynn Seely
SELL
7455 shares
2026-02-11
Stephen J Hill
SELL
1236 shares
2026-02-11
Gary K Lee
SELL
1671 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 52 HOLD |
